Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|December 12, 2017

SGS Adds GMP DNA Sequencing Capabilities at Glasgow Facility

SGS has introduced a Sanger sequencing service at its Glasgow, United Kingdom, laboratory to support genetic stability testing and perform identity testing on cell banks, plasmids, and viral seeds/vectors.

SGS, a provider of bio/pharmaceutical, analytical, and bioanalytical solutions, has introduced a Sanger sequencing service at its Glasgow, United Kingdom, laboratory to support genetic stability testing and perform identity testing on cell banks, plasmids, and viral seeds/vectors. The service is now available under good manufacturing practice (GMP) conditions to clients from December 2017.

Sanger sequencing is a method of DNA sequencing based on the selective incorporation of chain-terminating deoxynucleotides by DNA polymerase during in-vitro DNA replication. Applications include cell bank characterization, virus seed and plasmid identity testing, and genetic stability testing of cell banks. The new service is supported by an investment in ABI Life Technologies’ validated 3500xl DNA sequencing technology and will complement existing services for this testing, to provide comprehensive analysis and characterization solutions for clients involved in the production and manufacturing of biopharmaceutical products.

The Glasgow facility became part of SGS in 2012 following the acquisition of biopharmaceutical contract testing organization Vitrology Limited, which specializes in biosafety testing. An expansion of the facility in 2014 added an additional 500 m² of laboratory space.

SGS has 20 laboratories offering contract analytical and bioanalytical services across in North America, Europe, and Asia. The company delivers harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I­–IV clinical trial management, and services encompassing data management and statistics, pharmacokinetic/pharmacodynamic modeling and simulation, pharmacovigilance, and regulatory consultancy.

Source: SGS


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.